Indevus’ Valstar Is “Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency seeks clarification of manufacturing validation protocols described in the firm’s sNDA for the bladder cancer treatment.
You may also be interested in...
Indevus Submits Nebido For Hypogonadism
The long-acting testosterone could offer once every 12 week dosing compared to current treatment every two to three weeks.
Indevus Submits Nebido For Hypogonadism
The long-acting testosterone could offer once every 12 week dosing compared to current treatment every two to three weeks.
Indevus Gains Sanctura XR Approval
The molecule’s “highly differentiated profile” will set it apart from others in the crowded urinary incontinence space, Indevus tells “The Pink Sheet” DAILY.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: